Related Experiment Videos
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout:
S Timilsina1, K Brittan1, J R O'Dell1
1VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States; University of Nebraska Medical Center, Omaha, NE, United States.
Contemporary Clinical Trials
|March 30, 2018
Summary
This study compares allopurinol and febuxostat in gout management using a treat-to-target strategy. It aims to demonstrate the effectiveness of gradual urate-lowering therapy dose escalation for optimal patient outcomes.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Trials
Background:
- Suboptimal administration of urate-lowering therapy (ULT) is common in gout patients.
- Current treatment comparisons often use fixed, low doses of xanthine oxidase inhibitors.
- There is a need to evaluate ULTs like allopurinol and febuxostat with guideline-congruent strategies.
Purpose of the Study:
- To compare the effectiveness of allopurinol versus febuxostat in gout patients.
- To evaluate the impact of a "treat-to-target" strategy with dose titration.
- To assess gout flares under optimized ULT regimens.
Main Methods:
- A large, double-blind, non-inferiority trial (VA CSP 594) enrolling 950 gout patients.
- Randomization to either allopurinol or febuxostat with gradual dose titration over 72 weeks.
- Primary outcome: proportion of participants experiencing gout flares during Phase 3 (weeks 48-72).
Main Results:
- Study is ongoing; results not yet available.
- The study is designed to provide robust comparative effectiveness data.
- Long-term outcomes will be assessed for up to 10 years post-study.
Conclusions:
- The study will highlight the importance of gradual ULT dose escalation.
- It aims to confirm the value of a "treat-to-target" approach in gout management.
- Findings will inform optimal ULT strategies for gout patients.
Related Concept Videos
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...